FDA Issues Warning to Savannah Chrisley's GoodGirlRX Over Compounded Drug Claims

The U.S. Food and Drug Administration (FDA) has issued a warning letter to Savannah Chrisley regarding her website, GoodGirlRX. The warning specifically addressed claims made about compounded semaglutide and tirzepatide products.

Regulatory Concerns

The FDA reviewed the GoodGirlRX website and identified specific claims as potentially misleading. The website used phrases such as "FDA-approved meds," "FDA-approved options," and "clinically proven GLP-1 results" when referring to compounded drug products.

The FDA clarified that compounded drug products, like those offered by GoodGirlRX, are not FDA-approved.

The agency stated that these claims implied the products had undergone evaluation for safety and effectiveness, a process which has not occurred for these compounded items.

Subsequent Actions

The FDA notified Chrisley that the claims were in violation of federal law. A period of 15 business days was allotted for the website to make necessary corrections to avoid potential legal action.

Following the warning, the GoodGirlRX website implemented changes. This included altering phrases from "clinically proven results" to "clinically studied results." Disclaimers indicating that the GLP-1 drugs are not FDA-approved have also been added to the site.